The UNC FAI clinic team conducts research with human subjects in the Clinical & Translational Research Center (CTRC). The team has extensive experience in conducting oral food challenges, treating anaphylaxis, and surveying the ongoing health and well-being of our participants. Our clinical coordinators excel in providing education, reassurance, and support to all participants and families volunteering their time to our research.
Currently Enrolling
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
Study Overview: Phase 2 clinical trial to evaluate the investigational medicine RPT904 for the treatment of food allergy. RPT904 has the potential to be dosed every 8-12 weeks vs every 2 or 4 weeks for omalizumab.
Who Can Participate: Age 12-55, documented allergy to at least one of the following foods: peanut, milk, egg, cashew, or walnut
Contact Information: Latoya Obende | hilllr@email.unc.edu
Study details
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
Study Overview: The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Who Can Participate: Age 1-3 years, Physician-diagnosed peanut allergy and following a strict peanut-free diet
Contact Information: Deanna Hamilton | dhamilto@email.unc.edu
Study details
Omalizumab Weight Based Dosing Efficacy
Study Overview: The goal of this study is to learn how well high and low doses of the study drug, omalizumab, work and compare how safe it is to the current dosing scheme with multiple food allergies, regardless of total IgE.
Who Can Participate: Age 1-55, allergic to 2 of the following: peanut, milk, egg, walnut, cashew
Contact Information: Megan Nashel | Megan_Nashel@med.unc.edu
Study details
Hydrolyzed Formula in Infants and Children with Cow’s Milk Allergy
Study Overview: The purpose of this study is to qualify an extensively hydrolyzed casein-based infant formula as hypoallergenic according to the standards published by the American Academy of Pediatrics.
Who Can Participate: Children age 3 months to 12 years with a cow’s milk allergy
Contact Information: Deanna Hamilton | dhamilto@email.unc.edu
Study details
Ongoing, but Closed to Enrollment
Peanut Sublingual Immunotherapy (SLIT)- Tablet for Treatment of Peanut Allergy [more]
Systems Biology of Early Atopy (SUNBEAM) [more]
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy [more]
Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity, & Efficacy (VITESSE) [more]
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH) [more]
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy [more]
EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX) [more]
Interested in participating in a study?
Study Center Location
Questions?
Contact us at foodallergy@unc.edu